RARE
NASDAQ · Biotechnology
Ultragenyx Pharmaceutical In
$27.44
+0.53 (+1.97%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
-19.74%
1Y
-25.50%
YTD
+16.27%
Open$27.54
Previous Close$26.91
Day High$28.18
Day Low$27.31
52W High$42.37
52W Low$18.29
Volume—
Avg Volume2.00M
Market Cap2.70B
P/E Ratio—
EPS$-6.10
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$26.56
Above
SMA 200
$31.06
Below
RSI (14)
37.4
Neutral
Trend
Death Cross
Bearish
Analyst Ratings
Strong Buy
25 analysts
Price Target
+171.3% upside
Current
$27.44
$27.44
Target
$74.44
$74.44
$68.49
$74.44 avg
$103.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 757.56M | 616.85M | 933.24M |
| Net Income | -647,234,411 | -474,318,842 | 54.30M |
| Profit Margin | -85.4% | -81.2% | 5.8% |
| EBITDA | -593,205,721 | -458,875,852 | 81.20M |
| Free Cash Flow | — | — | 84.57M |
| Rev Growth | +22.8% | +22.8% | -2.9% |
| Debt/Equity | 3.41 | 3.41 | 0.13 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $230.01 | +6.25% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $344.72 | +2.11% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $124.87 | +0.90% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $466.79 | +3.36% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $612.50 | +0.42% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.41 | +2.99% | 64.3 | 37.13B |